Skip to content

Bicara Therapeutics BCAX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

ePlus logo
ePlusPLUS
$1.85M+1.4%
Whirlpool logo
WhirlpoolWHR
$524M
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$1.7M
HWK
HawkinsHWKN
$760K+14.4%
SkyWest logo
SkyWestSKYW
$1.31M+1.5%
PureCycle Technologies, Inc. logo
PureCycle Technologies, Inc.PCT
$0-100%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's stock issuance proceeds?
Bicara Therapeutics (BCAX) reported stock issuance proceeds of $161.76M in Q1 2026.
What does stock issuance proceeds mean?
Measures the total cash proceeds received from the sale of common equity to investors, net of issuance costs. This is a critical indicator of the company's ability to raise capital to fund ongoing clinical trials and research operations.